Axsome Q2 Revenue Jumps 46% to $218M, AUVELITY Alzheimer's Launch Drives Growth
AXSM has more than doubled off its 52-week low of $101.883.
Summary
Axsome Therapeutics reported Q2 2026 revenue of $218.4 million, a 46% increase driven by AUVELITY's Alzheimer's agitation launch and continued MDD growth. The company expects its cash to fund operations to profitability, and its pipeline advanced with new ADHD trials and an upcoming PDUFA for AXS-12.
Key Events · Earnings and Guidance · AXSM
-
Q2 Revenue Surges 46% to $218.4M
Total net product revenue reached $218.4 million, with AUVELITY contributing $180.3 million (up 51% YoY) and SUNOSI $35.8 million (up 20% YoY). SYMBRAVO added $2.3 million in its first full year.
-
AUVELITY Alzheimer's Launch Off to Strong Start
Launched in June 2026 for agitation in Alzheimer's dementia, AUVELITY saw new-to-brand prescriptions among patients 65+ increase 126% in the first eight weeks versus the prior quarter, signaling rapid adoption.
-
Cash Runway to Profitability Reaffirmed
With $319.9 million in cash as of June 30, 2026, management stated current cash is sufficient to fund operations into cash flow positivity, eliminating near-term dilution risk.
-
Pipeline Advances with ADHD Trials and PDUFA Date
FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in pediatric ADHD were initiated. AXS-12 for narcolepsy cataplexy has a PDUFA target action date of May 1, 2027.
Analysis · AXSM · Life Sciences
Axsome's Q2 results show accelerating commercial momentum with total product revenue up 46% year-over-year to $218.4 million, led by AUVELITY's 51% growth. The June launch of AUVELITY for Alzheimer's disease agitation is off to a strong start, with new-to-brand prescriptions among patients 65+ surging 126% in the first eight weeks. The company reiterated that its $319.9 million cash position is sufficient to reach cash flow positivity, removing near-term financing risk. Pipeline progress includes initiation of pediatric ADHD trials for solriamfetol and a PDUFA date of May 1, 2027 for AXS-12 in narcolepsy. The net loss widened slightly to $51.3 million, but the revenue trajectory and cash runway guidance are the dominant signals.
At the time of this filing, AXSM was trading at $207.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $101.88 to $260.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.